Supplementary Figure 1. Study design of 5-year extension study of GO-BEFORE and GO-FORWARD trials. The time point of database lock and unblinding was week 52. The GO-BEFORE and GO-FORWARD trials included patients with methotrexate (MTX) naïve and inadequate response to MTX, respectively. Each of the 30 patients from the GO-BEFORE and GO-FORWARD trials was included in this study. In both the GO-BEFORE and GO-FORWARD trials, patients were randomly assigned to receive: placebo injections plus MTX (group 1), golimumab 100 mg injections plus placebo capsules (group 2), golimumab 50 mg injections plus MTX (group 3), or golimumab 100 mg injections plus MTX (group 4) until week 52. The dose of golimumab and MTX could be adjusted after week 52 (at the time of database lock and unblinding) for up to 5 years, even in group 2.